<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02068521</url>
  </required_header>
  <id_info>
    <org_study_id>13VR3</org_study_id>
    <nct_id>NCT02068521</nct_id>
  </id_info>
  <brief_title>Versartis Long-Term Safety Study of Somavaratan</brief_title>
  <acronym>VISTA</acronym>
  <official_title>An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versartis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Versartis Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protocol 13VR3 is is a multi-center, open-label study assessing long-term somavaratan&#xD;
      administration.&#xD;
&#xD;
      Patients will be monitored for safety throughout their participation in the study. Safety&#xD;
      will be monitored by physical examination, inspection of injection sites, vital signs,&#xD;
      clinical laboratory determinations (including fasting glucose, insulin, and lipids), 12-lead&#xD;
      ECGs (for new treatment naïve subjects and subjects not previously exposed to somavaratan),&#xD;
      PK/PD assessments, and immunogenicity assessments.&#xD;
&#xD;
      Adverse events (AEs) and concomitant medications will be captured. AEs will be coded using&#xD;
      CTCAE v 4.0. AEs will be coded using the MedDRA dictionary and CMs using the WHO Drug&#xD;
      dictionary.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol 13VR3 is a multi-center, open-label study assessing long-term somavaratan&#xD;
      administration. It is open to subjects completing a somavaratan study in children with growth&#xD;
      hormone deficiency (GHD), as well as up to 100 new treatment naïve subjects with GHD. All&#xD;
      subjects will receive somavaratan 3.5 mg/kg twice monthly. The study will be conducted at&#xD;
      approximately 70 Pediatric Endocrinology centers in the United States, Canada, and Europe.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The primary endpoint of non-inferiority to daily therapy in the pediatric Phase 3 study was not&#xD;
    achieved&#xD;
  </why_stopped>
  <start_date type="Actual">March 3, 2014</start_date>
  <completion_date type="Actual">November 17, 2017</completion_date>
  <primary_completion_date type="Actual">November 17, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Safety assessments include recording of adverse events and concomitant medications, monitoring of injection sites, vital signs and clinical laboratory determinations.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Evaluate the changes in pharmacodynamics (PD) responses, bone age, weight, height velocity, height standard deviation scores, metabolic parameters, pubertal development and anti-drug antibody responses during long-term somavaratan treatment</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>PK/PD peak and trough measurements will be assessed throughout the study with assessment of plasma VRS-317 concentrations and IGF-I and its binding proteins measured at pre-specified time points.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">385</enrollment>
  <condition>Pediatric Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>Treatment naive subjects with GHD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 100 new treatment naïve subjects with GHD will receive somavaratan 3.5mg/kg twice monthly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects who have completed a somavaratan study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects after participation in (12VR2) or participation in the 14VR4 protocols have the option to receive somavaratan 3.5mg/kg twice monthly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somavaratan</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Subjects who have completed a somavaratan study</arm_group_label>
    <arm_group_label>Treatment naive subjects with GHD</arm_group_label>
    <other_name>VRS-317</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Subjects Completing a Previous Somavaratan Study:&#xD;
&#xD;
          1. Completion of a somavaratan clinical study.&#xD;
&#xD;
          2. Willing and able to comply with all study procedures.&#xD;
&#xD;
        Exclusion Criteria for Subjects Completing a Previous somavaratan Study:&#xD;
&#xD;
          1. Withdrawal from a somavaratan clinical study.&#xD;
&#xD;
          2. Use of certain medications with potential to alter responses to the test product.&#xD;
&#xD;
          3. Presence of a significant medical condition.&#xD;
&#xD;
        Inclusion Criteria for New Treatment Naïve Subjects:&#xD;
&#xD;
          1. Chronological Age ≥ 3.0 years.&#xD;
&#xD;
          2. Pre-pubertal status.&#xD;
&#xD;
          3. Diagnosis of GHD as documented by two or more GH stimulation test results ≤ 10.0&#xD;
             ng/mL.&#xD;
&#xD;
          4. Normal thyroid function at Screening Visit in subjects not being treated for&#xD;
             hypothyroidism.&#xD;
&#xD;
          5. Normal adrenal function at Screening Visit or within 6 months of the Screening Visit,&#xD;
             in subjects not being treated for adrenal insufficiency. Subjects with adrenal&#xD;
             insufficiency must receive glucocorticoid treatment for a minimum of 4 weeks before&#xD;
             study drug administration.&#xD;
&#xD;
          6. Pathology relating to cause of GHD must be stable for at least 6 months prior to&#xD;
             screening.&#xD;
&#xD;
          7. Legally authorized representatives must be willing and able to give informed consent.&#xD;
&#xD;
        Exclusion Criteria for New Treatment Naïve Subjects:&#xD;
&#xD;
          1. Prior/concomitant treatment with any growth promoting agent.&#xD;
&#xD;
          2. Current, significant disease.&#xD;
&#xD;
          3. Chromosomal aneuploidy, significant gene mutations or confirmed diagnosis of a named&#xD;
             syndrome.&#xD;
&#xD;
          4. Birth weight and/or birth length less than 5th percentile for gestational age.&#xD;
&#xD;
          5. Prolonged daily use of anti-inflammatory doses of oral glucocorticoids.&#xD;
&#xD;
          6. Prior history of malignancy.&#xD;
&#xD;
          7. Treatment with an investigational drug in the 30 days prior to screening.&#xD;
&#xD;
          8. Known allergy to constituents of the study drug formulation.&#xD;
&#xD;
          9. Ocular findings suggestive of increased intracranial pressure and/or retinopathy at&#xD;
             screening.&#xD;
&#xD;
         10. Significant spinal abnormalities including scoliosis, kyphosis, Chiari malformation,&#xD;
             and spina bifida variants.&#xD;
&#xD;
         11. Significant abnormality in screening studies.&#xD;
&#xD;
         12. History of pancreatitis or undiagnosed chronic abdominal pain.&#xD;
&#xD;
         13. History of spinal or total body irradiation.&#xD;
&#xD;
         14. Other pituitary hormone deficiencies that are not properly treated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Will Charlton, MD</last_name>
    <role>Study Director</role>
    <affiliation>Versartis Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://versartis.com</url>
    <description>Versartis website</description>
  </link>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>February 6, 2014</study_first_submitted>
  <study_first_submitted_qc>February 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2014</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Growth Hormone Deficiency</keyword>
  <keyword>Pediatric Growth Hormone Deficiency</keyword>
  <keyword>GHD</keyword>
  <keyword>PGHD</keyword>
  <keyword>VRS-317</keyword>
  <keyword>Versartis</keyword>
  <keyword>Growth disorder</keyword>
  <keyword>Long acting growth hormone</keyword>
  <keyword>Growth hormone</keyword>
  <keyword>Weekly growth hormone dosing</keyword>
  <keyword>Semi-monthly growth hormone dosing</keyword>
  <keyword>Monthly growth hormone dosing</keyword>
  <keyword>IGF-I</keyword>
  <keyword>Short stature</keyword>
  <keyword>Height velocity</keyword>
  <keyword>Annual height velocity</keyword>
  <keyword>Growth rate</keyword>
  <keyword>Somavaratan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism, Pituitary</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

